Literature DB >> 33718186

Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.

Sebastian Zahnreich1, Senayit Gebrekidan1, Gabriele Multhoff2,3, Peter Vaupel1, Heinz Schmidberger1, Arnulf Mayer1.   

Abstract

Abundance and signaling of the epidermal growth factor receptor (EGFR) and programmed cell death protein ligand 1 (PD-L1) in head and neck squamous cell carcinoma (HNSCC) are not only genetically determined but are also subject to the traits of the tumor microenvironment, which has hitherto not been clarified completely. We investigated the impact of hypoxia on the EGFR system and on PD-L1 in six HPV negative HNSCC cell lines in vitro and in FaDu xenografts in vivo. Protein levels of EGFR, AKT, pAKT, ERK1/2, pERK1/2, CA IX, cleaved PARP (apoptosis), LC3B (autophagy), and PD-L1 were quantified by western blot after oxygen deprivation or CoCl2, staurosporine, and erlotinib treatment. In FaDu xenograft tumors the expression of EGFR, CA IX andCD34 staining were analyzed. Reduced oxygen supply strongly downregulated EGFR protein levels and signaling in FaDu cells in vitro and in vivo, and a transient downregulation of EGFR signaling was found in three other HNSCC cell lines. PD-L1 was affected by oxygen deprivation in only one HNSCC cell line showing increased protein amounts. The results of this study indicate a significant impact of the traits of the tumor microenvironment on crucial molecular targets of cancer therapies with high clinical relevance for therapy resistance and response in HNSCC.
Copyright © 2021 Zahnreich, Gebrekidan, Multhoff, Vaupel, Schmidberger and Mayer.

Entities:  

Keywords:  PD-L1; PI3K/AKT; Ras-MAPK pathway; apoptosis; autophagy; epidermal growth factor receptor; head and neck cancer; hypoxia

Year:  2021        PMID: 33718186      PMCID: PMC7953989          DOI: 10.3389/fonc.2021.623964

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  53 in total

1.  HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.

Authors:  Xin Wang; Abraham Schneider
Journal:  Carcinogenesis       Date:  2010-04-15       Impact factor: 4.944

2.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

3.  PHD3 regulates EGFR internalization and signalling in tumours.

Authors:  Boyan K Garvalov; Franziska Foss; Anne-Theres Henze; Ioanna Bethani; Sabine Gräf-Höchst; Devendra Singh; Alina Filatova; Higinio Dopeso; Sascha Seidel; Miriam Damm; Amparo Acker-Palmer; Till Acker
Journal:  Nat Commun       Date:  2014-11-25       Impact factor: 14.919

4.  GABARAPL1 is required for increased EGFR membrane expression during hypoxia.

Authors:  Tom G Keulers; Marco B E Schaaf; Hanneke J M Peeters; Kim G M Savelkouls; Marc A Vooijs; Johan Bussink; Barry Jutten; Kasper M A Rouschop
Journal:  Radiother Oncol       Date:  2015-07-08       Impact factor: 6.280

Review 5.  Biology of interactions: antiepidermal growth factor receptor agents.

Authors:  Paul M Harari; Gregory W Allen; James A Bonner
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

6.  Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Authors:  Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

7.  Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.

Authors:  Sumita Trivedi; Raghvendra M Srivastava; Fernando Concha-Benavente; Soldano Ferrone; Tatiana M Garcia-Bates; Jing Li; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2016-05-23       Impact factor: 12.531

8.  Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR.

Authors:  Anne-Theres Henze; Boyan K Garvalov; Sascha Seidel; Angel M Cuesta; Mathias Ritter; Alina Filatova; Franziska Foss; Higinio Dopeso; Clara L Essmann; Patrick H Maxwell; Guido Reifenberger; Peter Carmeliet; Amparo Acker-Palmer; Till Acker
Journal:  Nat Commun       Date:  2014-11-25       Impact factor: 14.919

Review 9.  Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.

Authors:  Hiro Sato; Penny A Jeggo; Atsushi Shibata
Journal:  Cancer Sci       Date:  2019-10-04       Impact factor: 6.716

10.  EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.

Authors:  Shunli Peng; Rong Wang; Xiaojuan Zhang; Yueyun Ma; Longhui Zhong; Ke Li; Akihiro Nishiyama; Sachiko Arai; Seiji Yano; Wei Wang
Journal:  Mol Cancer       Date:  2019-11-20       Impact factor: 27.401

View more
  1 in total

Review 1.  TMEM16A as a potential treatment target for head and neck cancer.

Authors:  Kohei Okuyama; Souichi Yanamoto
Journal:  J Exp Clin Cancer Res       Date:  2022-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.